{"id":"W4389608093","doi":"10.1016/s1470-2045(23)00539-9","title":"Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"National Health and Medical Research Council; F. Hoffmann-La Roche; Roche","keywords":"Atezolizumab; Metastatic Urothelial Carcinoma; Medicine; Placebo; Internal medicine; Oncology; Chemotherapy; Cancer; Bladder cancer; Pembrolizumab; Immunotherapy; Urothelial carcinoma; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003102212,0.001595093,0.004032257,0.0004578998,0.0002824046,0.001138645,0.001031505,0.00163915,0.003955411],"category_scores_gemma":[0.001988091,0.0005847834,0.004560413,0.0005504429,0.001267103,0.001194006,0.0005973977,0.003806685,0.0005822945],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009033483,"about_ca_system_score_gemma":0.000902699,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001122855,"about_ca_topic_score_gemma":0.002690268,"domain_scores_codex":[0.9988538,0.0007689408,0.00004687528,0.0001323381,0.00005688887,0.0001410832],"domain_scores_gemma":[0.9986511,0.0005309389,0.000295138,0.0001252199,0.00005247501,0.000345136],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9766886,0.00235711,0.0006127163,0.0006629347,0.001683168,0.00002715893,0.00005213308,0.0006412102,0.002101397,0.00007382969,0.0005270866,0.01457278],"study_design_scores_gemma":[0.8800161,0.1127045,0.004133273,0.00005553961,0.00163067,0.00003635661,0.00003613418,0.0004389712,0.0002926945,0.000156442,0.0004737791,0.00002558851],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9891133,0.006192375,0.000561239,0.0005428115,0.0003559541,0.0009815665,0.001054757,0.00008215001,0.001115806],"genre_scores_gemma":[0.9902695,0.003238754,0.000940089,0.0008658061,0.0003015527,0.00106451,0.001468406,0.00004270939,0.001808785],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004032257,"threshold_uncertainty_score":0.01640624,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09030359634918199,"score_gpt":0.3988979223683898,"score_spread":0.3085943260192078,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}